SYNH - Syneos Health, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 41.55 |
| Open | 41.56 |
| Bid | 41.53 x 1800 |
| Ask | 41.60 x 1400 |
| Day's Range | 41.55 - 41.77 |
| 52 Week Range | 22.89 - 79.77 |
| Volume | |
| Avg. Volume | 2,414,476 |
| Market Cap | 4.312B |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | 28.89 |
| EPS (TTM) | 1.44 |
| Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.56 |
Fair Value
Related Research
GlobeNewswireSyneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity
Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across OrganizationMORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Batisha Anson to the newly created role of Global Head of Patient Diversity and Health Equity. In this role, Anson will advance Syneos Health’s goal to improve diverse representation of pati
- GlobeNewswire
Syneos Health Leaders Recognized by HBA
Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry ImpactMORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer Sozio, SVP Clinical Operations, FSP360, and Caitlin Purinai, Senior Director, Human Resources Business Partner, have been recognized by the Healthcare Businesswomen’s Association (HBA) as admirable female
- GlobeNewswire
Syneos Health Leaders Recognized as PM360 2023 ELITE Award Recipients
Company Executives Honored for Notable Biopharmaceutical Industry ImpactMORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual
ZacksSyneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
ZacksSyneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
BenzingaSyneos To Be Acquired By Private Investment Consortium For $7.1B, Q1 Earnings Beat Expectations
Syneos Health Inc (NASDAQ: SYNH) reported the first quarter of FY23 revenues of $1.357 billion, beating the analyst consensus of $1.28 billion. Revenues inched up 1.5% year over year. The integrated biopharmaceutical solutions company posted an adjusted EPS of $0.75, -25.7% Y/Y, beating the analyst consensus of $0.66. The company has entered into a definitive agreement worth $7.1 billion to be acquired by a private investment consortium consisting Elliott Investment Management, Patient Square Ca
ZacksSyneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates
Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BenzingaSyneos Health Close To Being Acquired For $7B - Elliott, Patient Square and Veritas Investment Consortium Lead Deal
A group of investors, including Elliott Investment Management, Patient Square Capital, and Veritas Capital, is close to acquiring Syneos Health Inc (NASDAQ: SYNH) for more than $7 billion, including debt. Bloomberg News first reported the news of the investment consortium's talks with Syneos. The consortium will pay about $43 per share in cash for Syneos, representing a 14% gain to Syneos' value on February 24, the last trading day before Reuters reported that the company was exploring a sale. T
Barrons.comSyneos Health Stock Rises on $7.1 Billion Sale Amid Biotech Spending Slowdown
The sale of Syneos Health comes as the company faces muted spending from drug developers for its clinical-research services.
- GlobeNewswire
Syneos Health Reports First Quarter 2023 Results
Revenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $713.6 million for the first quarter, a year-over-year decline of 42.5% and abook-to-bill ratio of 0.70x, and $2,313.3 million for the trailing twelve months, a year-over-year decline of 47.3% and a book-to-bill ratio of 0.57x.Excluding
ReutersSyneos taken private for $4.46 billion by investment consortium
The consortium will pay about $43 per share in cash, which represents a premium of about 12% to Syneos' last close. North Carolina-based Syneos has been facing challenges in winning new business as many of its clients, which include small and medium-sized biotech companies, have cut spending amid difficulties raising funding in a post-COVID market downturn. Other companies which offer contract research services, such as Danaher Corp and Thermo Fisher Scientific, have also flagged soft demand in the sector.
- Reuters
UPDATE 3-Syneos taken private for $4.46 bln by investment consortium
An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to take Syneos Health Inc private for $4.46 billion, the contract research firm said on Wednesday. The consortium will pay about $43 per share in cash, which represents a premium of about 12% to Syneos' last close. North Carolina-based Syneos has been facing challenges in winning new business as many of its clients, which include small and medium-sized biotech companies, have cut spending amid difficulties raising funding in a post-COVID market downturn.
- GlobeNewswire
Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion
Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management (“Elliott”), Patient Square Capital
BloombergElliott, Patient Square and Veritas Near Takeover of Syneos
(Bloomberg) -- A consortium including Elliott Investment Management is in advanced talks to acquire Syneos Health Inc., according to people familiar with the matter.Most Read from BloombergSteve Schwarzman Holds Off Giving Money to DeSantis After Meeting HimUS Inflation Shows Signs of Moderating, Giving Fed Room to PauseItaly Intends to Exit China Belt and Road Pact as Ties SourVanguard’s Trillion-Dollar Man Leads a Fixed-Income RevolutionTrump Liable for Sex Abuse, Must Pay $5 Million to Carrol
- Investing.com
Airbnb, Twilio and Virgin Galactic fall premarket; Rivian rises
Investing.com -- Stocks in focus in premarket trade on Wednesday, May 10th. Please refresh for updates.
- Reuters
UPDATE 2-Investment consortium nears $7 bln-plus deal for Syneos Health -sources
A consortium comprising Elliott Investment Management, Patient Square Capital and Veritas Capital is nearing a deal to acquire Syneos Health Inc , a provider of clinical research to drug developers, for more than $7 billion, including debt, people familiar with the matter said. The consortium will pay about $43 per share in cash for Syneos, the sources said. Syneos Chief Executive Michelle Keefe said in February the company had "work to do" to improve its win rates among small drug firms for which it relies on for a big chunk of its business.
- Reuters
Investment consortium nears deal for Syneos Health-sources
A consortium comprising Elliott Investment Management, Patient Square Capital and Veritas Capital is nearing a deal to acquire Syneos Health Inc , a provider of clinical research to drug developers with a market value of $4 billion, people familiar with the matter said. The price that the consortium is paying for Syneos could not be learned. Syneos and the investment firms did not immediately respond to requests for comment.
ZacksHere's Why Investors Should Retain Syneos Health (SYNH) for Now
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
Simply Wall St.Is Syneos Health, Inc.'s (NASDAQ:SYNH) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Syneos Health's (NASDAQ:SYNH) stock increased significantly by 6.7% over the...
- GlobeNewswire
Syneos Health Appoints Michael Bonello as Chief Financial Officer
Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research IndustryMORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as Chief Financial Officer, effective July 1, 2023. Stanford (Ben) Rudnick will continue to serve as Interim Chief Financial Officer until that time. Mr. Bonello has more than 30 years of financial leadersh
ZacksAutolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
ZacksNextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care
NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.
- GlobeNewswire
Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023
MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register
- Simply Wall St.
Syneos Health, Inc.'s (NASDAQ:SYNH) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Syneos Health fair value estimate is US$67.23 Syneos Health is...
- GlobeNewswire
Syneos Health Wins 2023 ViE Award
Company Recognized for Positive Vaccine Expertise ContributionsMORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for Best Contract Research Organization (CRO). Presented at the 2023 World Vaccine Congress in Washington, D.C., the award recognizes the vaccine industry’s most outstanding efforts, accomplishments and positiv